mardi 10 octobre 2017

Onco Actu du 10 octobre 2017

1. Biologie

Cancer-genome study challenges mouse 'avatars' [Nature]

2.6 Etiologie - Environnement

Three quarters of honey samples contain pesticide traces [NHS Choices]

5.1 Traitements - Pré-clinique

There Are Probes, And There Are Probes [In the Pipeline]

5.10 Traitements - Essais

Lilly Reports Topline Results from Phase 3 JUNIPER Trial Evaluating Verzenio™ (abemaciclib) in KRAS-Mutated, Advanced Non-Small Cell Lung Cancer [Lilly]

5.12 Immunothérapies

Recent Advances in Measuring Response to Immune Checkpoint Inhibitors [Cancer Research Catalyst]

5.12.7 Immunothérapies - vaccins

AbbVie jumps on the oncolytics bandwagon, embracing Turnstone in new collaboration [EndPoints]

5.2 Pharma

Bristol-Myers lures Saha back from biotech to take SVP post [FierceBiotech]

Bristol-Myers Squibb Appoints Saurabh Saha, M.D., Ph.D., as Senior Vice President, Global Head of Translational Medicine [BMS]

Biotech Firm Incyte Finds The Right Chemistry For Success [Forbes]

Biotech scientist/entrepreneur Saurabh Saha makes an unusual return to the arms of a big — and excessively discreet — R&D group [EndPoints]

AstraZeneca gets cancer drug boost as shares claw back £10bn Mystic trial losses [The Telegraph]

5.2.1 Pharma - Partenariats

Genmab and Seattle Genetics to Initiate New Study of Novel Antibody-Drug Conjugate Tisotumab Vedotin in Cervical Cancer [Genmab]

5.2.3 Pharma - économie

Erytech seeks $100M IPO for pivotal tumor starvation trial [FierceBiotech]

5.3 Traitements - FDA, EMA, NICE...

Many new cancer drugs show 'no clear benefit', argues review [NHS Choices]

5.4 Traitements - Economie

California governor, rebuffing pharma pleas, signs breakthrough drug pricing bill [FiercePharma]

A Flawed Study Depicts Drug Companies as Profiteers [Wall Street Journal]

6.1 Observation

Aggressive breast cancer treatment tied to more missed work [Reuters]

6.8 Communication

Updating Wikipedia should be part of all doctors’ jobs [STAT]

‘Ethical bordellos:’ Op-eds don’t always disclose Big Pharma conflicts of interest [HealthNewsReview]